{
    "id": "5c6583117c78d69471000002",
    "question": "Can midostaurin inhibit angiogenesis?",
    "options": {
        "A": "yes",
        "B": "no"
    },
    "answer": "A",
    "predict": "{\"step_by_step_thinking\": \"To answer this question, we need to understand the function of midostaurin and its role in angiogenesis. Midostaurin is a tyrosine kinase inhibitor that targets mutant proteins, including those involved in angiogenesis. Specifically, it inhibits the BCR-ABL and FLT3 kinases, which are often mutated in certain types of cancer, including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Angiogenesis is the process by which new blood vessels form from pre-existing vessels, and it is a critical component of tumor growth and metastasis. Midostaurin, as a tyrosine kinase inhibitor, can inhibit angiogenesis by blocking the signaling pathways that promote the formation of new blood vessels. Therefore, based on its mechanism of action, midostaurin can inhibit angiogenesis.\", \"answer_choice\": \"A\"}",
    "snippets": [
        {
            "id": "InternalMed_Harrison_6215",
            "title": "InternalMed_Harrison",
            "content": "Angiogenesis inhibitors function by targeting the critical molecular pathways involved in EC proliferation, migration, and/or survival, many of which are unique to the activated endothelium in tumors. Inhibition of growth factor and adhesion-dependent signaling pathways can induce EC apoptosis with concomitant inhibition of tumor growth. Different types of tumors can use distinct combinations of molecular mechanisms to activate the angiogenic switch. Therefore, it is doubtful that a single antiangiogenic strategy will suffice for all human cancers; rather, a number of agents or combinations of agents will be needed, depending on distinct programs of angiogenesis used by different human cancers. Despite this, experimental data indicate that for some tumor types, blockade of a single growth factor (e.g., VEGF) may inhibit tumor-induced vascular growth. A. Normal blood vessel B. Tumor blood vessel"
        },
        {
            "id": "Surgery_Schwartz_2113",
            "title": "Surgery_Schwartz",
            "content": "cell survival via a paracrine effect.23 The angiopoietins, angiopoietin-1 and angiopoietin-2 (Ang-1 and Ang-2), are thought to regulate blood vessel maturation. Ang-1 and Ang-2 both bind to the angiopoietin-1 receptor (also known as tyrosine-protein kinase receptor TIE-2), but only the binding of Ang-1 activates signal transduction; thus Ang-2 is an Ang-1 antagonist. Ang-1, via the Tie-2 receptor, induces remodel-ing and stabilization of blood vessels. Therefore, the balance between these factors determines the angiogenetic capacity of a tumor.Tumor angiogenesis is regulated by several factors in a coordinated fashion. In addition to upregulation of proangiogenic molecules, angiogenesis also can be encouraged by suppression of naturally occurring inhibitors. Such inhibitors of angiogen-esis include thrombospondin 1 and angiostatin. Angiogenesis is a prerequisite not only for primary tumor growth but also for metastasis. Angiogenesis in the primary tumor, as determined by microvessel"
        },
        {
            "id": "InternalMed_Harrison_6225",
            "title": "InternalMed_Harrison",
            "content": "FIGuRE 102e-12 Knowledge of the molecular events governing tumor angiogenesis has led to a number of therapeutic strategies to block tumor blood vessel formation. The successful therapeutic targeting of VEGF is described in the text. Other endothelial cell\u2013 specific receptor tyrosine kinase pathways (e.g., angiopoietin/Tie2 and ephrin/EPH) are likely targets for the future. Ligation of the \u03b1v\u03b23 integrin is required for endothelial cell (EC) survival. Integrins are also required for EC migration and are important regulators of matrix metalloproteinase (MMP) activity, which modulates EC movement through the extracellular matrix (ECM) as well as release of bound growth factors. Targeting of integrins includes development of blocking antibodies, small peptide inhibitors of integrin signaling, and arg-gly-asp\u2013containing peptides that prevent integrin:ECM binding. Peptides derived from normal proteins by proteolytic cleavage, including endostatin and tumstatin, inhibit angiogenesis by"
        },
        {
            "id": "Pathology_Robbins_1320",
            "title": "Pathology_Robbins",
            "content": "The idea that angiogenesis is essential if solid tumors are to grow to clinically significant sizes has provided a powerful impetus for the development of therapeutic agents that block angiogenesis. These agents are now a part of the armamentarium that oncologists use against cancers; a cardinal example is bevacizumab, a monoclonal antibody that neutralizes VEGF activity and is approved for use in the treatment of multiple cancers. However, angiogenesis inhibitors have not been nearly as effective as was originally hoped; they can prolong life, but usually for only a few months and at high financial cost. The mechanisms that underlie the persistence and ultimate progression of cancers in the face of therapy with angiogenesis inhibitors are not yet clear. The modest benefit of anti-angiogenic therapy highlights the pernicious nature of advanced cancers, which can even elude therapies directed at stromal support cells such as endothelium."
        },
        {
            "id": "Pathology_Robbins_1316",
            "title": "Pathology_Robbins",
            "content": "How do growing tumors develop a blood supply? The current paradigm is that angiogenesis is controlled by a balance between angiogenesis promoters and inhibitors; in angiogenic tumors this balance is skewed in favor of promoters. Early in their development, most human tumors do not induce angiogenesis. Starved of nutrients, these tumors remain small or in situ, possibly for years, until an angiogenic switch terminates this stage of vascular quiescence. The molecular basis of the angiogenic switch involves increased production of angiogenic factors and/ or loss of angiogenic inhibitors. These factors may be produced by the tumor cells themselves or by inflammatory cells (e.g., macrophages) or resident stromal cells (e.g., tumor-associated fibroblasts). Proteases, either elaborated by the tumor cells or by stromal cells in response to the tumor, are also involved in regulating the balance between angiogenic and anti-angiogenic factors. Many proteases can release proangiogenic basic"
        },
        {
            "id": "Gynecology_Novak_7339",
            "title": "Gynecology_Novak",
            "content": "Targeted Therapies Knowledge of molecular pathways within normal and malignant cells is leading to the development of cancer treatment agents with specific molecular targets. There is great potential in targeting angiogenesis, in particular vascular endothelial growth factor (VEGF), which plays a major role in the biology of epithelial ovarian cancer (318). There are three main approaches to target angiogenesis: the first is to target VEGF itself, the second to target the VEGF receptor, and the third is to inhibit tyrosine kinase activation and downstream signaling with small molecules that work at the intracellular level."
        },
        {
            "id": "Pharmacology_Katzung_6159",
            "title": "Pharmacology_Katzung",
            "content": "Bevacizumab is a humanized IgG1 monoclonal antibody that binds to vascular endothelial growth factor (VEGF) and inhibits VEGF from binding to its receptor, especially on endothelial cells. It is an antiangiogenic drug that has been shown to inhibit growth of blood vessels (angiogenesis) in tumors. It is approved for firstand second-line treatment of patients with metastatic colorectal cancer alone or in combination with appropriate chemotherapy. It is also approved for treatment of non-small cell lung cancer, glioblastoma multiforme that has progressed after prior treatment, and metastatic kidney cancer when used with IFN-\u03b1. Since bevacizumab is antiangiogenic, it should not be administered until patients heal from surgery. Patients taking the drug should be watched for hemorrhage, gastrointestinal perforations, and wound healing problems. Bevacizumab has also been used off label by intravitreal injection to slow progression of neovascular macular degeneration (see ranibizumab under"
        },
        {
            "id": "Pathology_Robbins_1317",
            "title": "Pathology_Robbins",
            "content": "tumor cells or by stromal cells in response to the tumor, are also involved in regulating the balance between angiogenic and anti-angiogenic factors. Many proteases can release proangiogenic basic fibroblast growth factors (bFGF) that are stored in the ECM; conversely, the angiogenesis inhibitors angiostatin and endostatin are produced by proteolytic cleavage of plasminogen and collagen, respectively."
        },
        {
            "id": "Pathology_Robbins_539",
            "title": "Pathology_Robbins",
            "content": "Leading (\u201dtip\u201d) cell (VEGF, Notch Formation of new vessel ECM Pericyte recruitment Elongation of vascular stalk Fig. 3.25 Angiogenesis. In tissue repair, angiogenesis occurs mainly by the sprouting of new vessels. The steps in the process, and the major signals involved, are illustrated.The newly formed vessel joins up with other vessels (not shown) to form the new vascular bed. The process of angiogenesis involves several signaling pathways, cell\u2013cell interactions, ECM proteins, and tissue enzymes."
        },
        {
            "id": "Pathology_Robbins_537",
            "title": "Pathology_Robbins",
            "content": "Angiogenesis is the process of new blood vessel development from existing vessels. It is critical in healing at sites of injury, in the development of collateral circulations at sites of ischemia, and in allowing tumors to increase in size beyond the constraints of their original blood supply. Much work has been done to understand the mechanisms of angiogenesis, and therapies have been developed either to augment the process (e.g., to improve blood flow to a heart ravaged by coronary atherosclerosis) or to inhibit it (to frustrate tumor growth or block pathologic vessel growth, as in wet macular degeneration of the eye). Angiogenesis involves sprouting of new vessels from existing ones, and consists of the following steps ( Fig. 3.25 Vasodilation in response to NO and increased permeability induced by VEGF Separation of pericytes from the abluminal surface and breakdown of the basement membrane to allow formation of a vessel sprout"
        },
        {
            "id": "Surgery_Schwartz_2109",
            "title": "Surgery_Schwartz",
            "content": "but also growth factor\u2013binding proteins, growth factor precursors, cell adhesion molecules, and other proteinases to provide a growth advantage. The activity of MMPs is regulated by their endogenous inhibitors and tissue inhibitors of MMPs (TIMP-1, TIMP-2, TIMP-3, and TIMP-4).AngiogenesisAngiogenesis is the establishment of new blood vessels from a preexisting vascular bed. This neovascularization is essential for tumor growth and metastasis. Tumors develop an angiogenic phenotype as a result of accumulated genetic alterations and in response to local selection pressures such as hypoxia. Many of the common oncogenes and tumor-suppressor genes have been shown to play a role in the induction of angiogenesis.In response to the angiogenic switch, pericytes retract and the endothelium secretes several growth factors such as basic fibroblast growth factor, platelet-derived growth fac-tor (PDGF), and insulin-like growth factor. The basement membrane and stroma around the capillary are"
        },
        {
            "id": "Pharmacology_Katzung_5984",
            "title": "Pharmacology_Katzung",
            "content": "Bevacizumab, Ziv-Aflibercept, Ramucirumab, Sorafenib, Sunitinib, & Pazopanib Vascular endothelial growth factor (VEGF) is one of the most important angiogenic growth factors. The growth of both primary and metastatic solid tumors requires an intact vasculature; thus the VEGF signaling pathway represents an attractive target for chemotherapy. Several approaches have been taken to inhibit VEGF signaling; they include inhibition of VEGF interactions with its receptor by targeting either the VEGF ligand with antibodies or soluble chimeric decoy receptors, or by direct inhibition of VEGF receptor\u2013associated tyrosine kinase activity by small molecule inhibitors."
        },
        {
            "id": "InternalMed_Harrison_5440",
            "title": "InternalMed_Harrison",
            "content": "Gene transfer strategies have also been developed for inhibiting tumor angiogenesis. These have included constitutive expression of angiogenesis inhibitors such as angiostatin and endostatin; use of siRNA to reduce levels of VEGF or VEGF receptor; and combined approaches in which autologous T cells are genetically modified to recognize antigens specific to tumor vasculature. These studies are still in early-phase testing."
        },
        {
            "id": "InternalMed_Harrison_6226",
            "title": "InternalMed_Harrison",
            "content": "and arg-gly-asp\u2013containing peptides that prevent integrin:ECM binding. Peptides derived from normal proteins by proteolytic cleavage, including endostatin and tumstatin, inhibit angiogenesis by mechanisms that include interfering with integrin function. Signal transduction pathways that are dysregulated in tumor cells indirectly regulate EC function. Inhibition of EGF-family receptors, whose signaling activity is upregulated in a number of human cancers (e.g., breast, colon, and lung cancers), results in downregulation of VEGF and IL-8, while increasing expression of the antiangiogenic protein thrombospondin-1. The Ras/MAPK, PI3K/Akt, and Src kinase pathways constitute important antitumor targets that also regulate the proliferation and survival of tumor-derived EC. The discovery that ECs from normal tissues express tissue-specific \u201cvascular addressins\u201d on their cell surface suggests that targeting specific EC subsets may be possible."
        },
        {
            "id": "InternalMed_Harrison_6208",
            "title": "InternalMed_Harrison",
            "content": "proliferation, migration, and survival, whereas VEGFR1 may act as an antagonist of R2 in ECs but is probably also important for angioblast differentiation during embryogenesis. Tumor vessels may be more dependent on VEGFR signaling for growth and survival than normal ECs. Although VEGF signaling is a critical initiator of angiogenesis, this is a complex process regulated by additional signaling pathways (Fig. 102e-10). The angiopoietin, Ang1, produced by stromal cells, binds to the EC RTK Tie2 and promotes the interaction of ECs with the ECM and perivascular cells, such as pericytes and smooth-muscle cells, to form tight, nonleaky vessels. Platelet-derived growth factor (PDGF) and basic fibroblast growth factor (bFGF) help to recruit these perivascular cells. Ang1 is required for maintaining the quiescence and stability of mature blood vessels and prevents the vascular permeability normally induced by VEGF and inflammatory cytokines."
        },
        {
            "id": "Surgery_Schwartz_3913",
            "title": "Surgery_Schwartz",
            "content": "through several different mechanisms, including delivery of oxygen and nutrients and the secretion of growth-promoting cytokines by endothelial cells.191,192 VEGF induces its effect by binding to transmembrane tyrosine kinase recep-tors. Overexpression of VEGF in invasive breast cancer is cor-related with increased microvessel density and recurrence in node-negative breast cancer. An angiogenesis index has been developed in which microvessel density (CD31 expression) is combined with expression of thrombospondin (a negative modulator of angiogenesis) and p53 expression. Both VEGF expression and the angiogenesis index may have prognostic and predictive significance in breast cancer.193 Bevacizumab (a monoclonal antibody to VEGF) was approved by the FDA for use in metastatic breast cancer in combination with pacli-taxel chemotherapy. This approval was based on results from a phase 3 trial by the Eastern Cooperative Oncology Group. The group\u2019s E2100 trial showed that when bevacizumab was"
        },
        {
            "id": "InternalMed_Harrison_6207",
            "title": "InternalMed_Harrison",
            "content": "When tumor cells arise in or metastasize to an avascular area, they grow to a size limited by hypoxemia and nutrient deprivation. Hypoxemia, a key regulator of tumor angiogenesis, causes the transcriptional induction of the gene encoding VEGF. VEGF and its receptors are required for embryonic vasculogenesis (development of new blood vessels when none preexist) and normal (wound healing, corpus luteum formation) and pathologic angiogenesis (tumor angiogenesis, inflammatory conditions such as rheumatoid arthritis). VEGF-A is a heparin-binding glycoprotein with at least four isoforms (splice variants) that regulates blood vessel formation by binding to the RTKs VEGFR1 and VEGFR2, which are expressed on all ECs in addition to a subset of hematopoietic cells (Fig. 102e-9). VEGFR2 regulates EC proliferation, migration, and survival, whereas VEGFR1 may act as an antagonist of R2 in ECs but is probably also important for angioblast differentiation during embryogenesis. Tumor vessels may be"
        },
        {
            "id": "Pathology_Robbins_1321",
            "title": "Pathology_Robbins",
            "content": "Improvements are only possible with greater understanding of the \u201cescape routes\u201d through which tumor cells sidestep the effects of the angiogenesis inhibitors that are now in use. Vascularizationoftumorsisessentialfortheirgrowthandiscontrolledbythebalancebetweenangiogenicandantiangiogenicfactorsthatareproducedbytumorandstromalcells. HypoxiatriggersangiogenesisthroughtheactionsofHIF-1\u03b1 onthetranscriptionoftheproangiogenicfactorVEGF. Manyotherfactorsregulateangiogenesis;forexample,p53inducessynthesisoftheangiogenesisinhibitorthombospondin-1,whileRAS,MYC,andMAPKsignalingallupregulateVEGFexpressionandstimulateangiogenesis. VEGFinhibitorsareusedtotreatanumberofadvancedcancersandprolongtheclinicalcourse,butarenotcurative."
        },
        {
            "id": "Surgery_Schwartz_2114",
            "title": "Surgery_Schwartz",
            "content": "include thrombospondin 1 and angiostatin. Angiogenesis is a prerequisite not only for primary tumor growth but also for metastasis. Angiogenesis in the primary tumor, as determined by microvessel density, has been demonstrated to be an inde-pendent predictor of distant metastatic disease and survival in several cancers. Expression of angiogenic factors such as VEGFs has had prognostic value in many studies. These findings further emphasize the importance of angiogenesis in cancer biology.MetastasisMetastases arise from the spread of cancer cells from the pri-mary site and the formation of new tumors in distant sites. The metastatic process consists of a series of steps that need to be completed successfully (Fig. 10-8).27 First, the primary cancer must develop access to the circulation through either the blood circulatory system or the lymphatic system. After the cancer cells are shed into the circulation, they must survive. Next, the circulating cells lodge in a new organ and"
        },
        {
            "id": "InternalMed_Harrison_7105",
            "title": "InternalMed_Harrison",
            "content": "Kinase Inhibitors A survival advantage has been observed for the oral multikinase inhibitor, sorafenib (Nexavar), versus placebo in two randomized trials. It targets both the Raf mitogenic pathway and the vascular endothelial growth factor receptor (VEGFR) endothelial vasculogenesis pathway. However, tumor responses were negligible, and the survival in the treatment arm in Asians was less than the placebo arm in the Western trial (Table 111-7). Sorafenib has considerable toxicity, with 30\u201340% of patients requiring \u201cdrug holidays,\u201d dose reductions, or cessation of therapy. The most common toxicities include fatigue, hypertension, diarrhea, mucositis, and skin changes, such as the painful hand-foot syndrome, hair loss, and itching, each in 20\u201340% of patients. Several \u201clook-alike\u201d new agents that also target angiogenesis have either proved to be inferior or more toxic. These include sunitinib, brivanib, linifanib, everolimus, and bevacizumab (Table 111-8). The idea of angiogenesis alone"
        },
        {
            "id": "Pathology_Robbins_1314",
            "title": "Pathology_Robbins",
            "content": "factors (IGFs) and PDGF. While the resulting tumor vasculature is effective at delivering nutrients and removing wastes, it is not entirely normal; the vessels are leaky and dilated, and have a haphazard pattern of connection, features that can be appreciated on angiograms. By permitting tumor cells access to these abnormal vessels, angiogenesis also contributes to metastasis. Angiogenesis is thus an essential facet of malignancy."
        },
        {
            "id": "InternalMed_Harrison_6206",
            "title": "InternalMed_Harrison",
            "content": "angiogenic molecules, the most potent being vascular endothelial growth factors (VEGF), that induce the proliferation and migration of host ECs into the tumor. Sprouting in normal and pathogenic angiogenesis is regulated by three families of transmembrane receptor tyrosine kinases (RTKs) expressed on ECs and their ligands (VEGFs, angiopoietins, ephrins; Fig. 102e-10), which are produced by tumor cells, inflammatory cells, or stromal cells in the tumor microenvironment."
        },
        {
            "id": "InternalMed_Harrison_7106",
            "title": "InternalMed_Harrison",
            "content": "that also target angiogenesis have either proved to be inferior or more toxic. These include sunitinib, brivanib, linifanib, everolimus, and bevacizumab (Table 111-8). The idea of angiogenesis alone as a major HCC therapeutic target may need revision."
        },
        {
            "id": "Pathology_Robbins_1318",
            "title": "Pathology_Robbins",
            "content": "The local balance of angiogenic and anti-angiogenic factors is influenced by several factors: Relative lack of oxygen due to hypoxia stabilizes HIF1\u03b1, an oxygen-sensitive transcription factor mentioned earlier, which then activates the transcription of proangiogenic cytokines such as VEGF. These factors create an angiogenic gradient that stimulates the proliferation of endothelial cells and guides the growth of new vessels toward the tumor. Mutations involving tumor suppressors and oncogenes in cancers also tilt the balance in favor of angiogenesis. For example, p53 stimulates expression of antiangiogenic molecules, such as thrombospondin-1, and represses expression of proangiogenic molecules, such as VEGF. Thus, loss of p53 in tumor cells provides a more permissive environment for angiogenesis."
        },
        {
            "id": "Pathology_Robbins_1376",
            "title": "Pathology_Robbins",
            "content": "Angiogenesis. Inflammatory cells release numerous factors, including VEGF, that stimulate angiogenesis. Invasion and metastasis. Proteases released from macrophages foster tissue invasion by remodeling the ECM, while factors such as TNF and EGF may directly stimulate tumor cell motility. As mentioned earlier, other factors released from stromal cells such as TGF-\u03b2 may promote epithelial-mesenchymal transition (EMT), which may be a key event in the process of invasion and metastasis."
        },
        {
            "id": "First_Aid_Step1_230",
            "title": "First_Aid_Step1",
            "content": "FGF Stimulates angiogenesis TGF-\u03b2 Angiogenesis, fibrosis EGF Stimulates cell growth via tyrosine kinases (eg, EGFR/ErbB1) HISTOLOGY Focus of epithelioid cells (activated macrophages with abundant pink cytoplasm) surrounded by lymphocytes and multinucleated giant cells (formed by fusion of several activated macrophages). Two types: Caseating: associated with Central necrosis. Seen with infectious etiologies (eg, TB, fungal). Noncaseating A : no central necrosis. Seen with autoimmune diseases (eg, sarcoidosis, Crohn disease). APCs present antigens to CD4+ Th cells and secrete IL-12 \u2022 CD4+ Th cells differentiate into Th1 cells Th1 secretes IFN-\u03b3 \u2022 macrophage activation Macrophages \u008f cytokine secretion (eg, TNF) \u008e formation of epithelioid macrophages and giant cells. Anti-TNF therapy can cause sequestering granulomas to break down \u2022 disseminated disease. Always test for latent TB before starting anti-TNF therapy."
        },
        {
            "id": "InternalMed_Harrison_8523",
            "title": "InternalMed_Harrison",
            "content": "Trials comparing intensive chemotherapy and autologous and allogeneic HSCT have shown improved duration of remission with allogeneic HSCT compared to autologous HSCT or chemotherapy alone. However, overall survival is generally not different; the improved disease control with allogeneic HSCT is erased by the increase in fatal toxicity. In fact, relapse following allogeneic HSCT occurs in only a small fraction of patients, but treatment-related toxicity is relatively high; complications include venoocclusive disease, graft-versus-host disease (GVHD), and infections. Autologous HSCT can be administered in young and older patients and uses the same preparative regimens. Patients subsequently receive their own stem cells collected while in remission. The toxicity is relatively low with Class of Drugs Examples of Agents in Class Inhibitors of Mutant proteins Tyrosine kinase inhibitors Dasatinib, midostaurin, quizartinib, sorafenib IDH2 mutation inhibitor AG-221"
        },
        {
            "id": "First_Aid_Step1_483",
            "title": "First_Aid_Step1",
            "content": "Etoposide, teniposide mechanISm Inhibit topoisomerase II \u008e\u008f DNA degradation (cell cycle arrest in G2 and S phases). clInIcal USe Solid tumors (particularly testicular and small cell lung cancer), leukemias, lymphomas. adVeRSe eFFectS Myelosuppression, alopecia. Irinotecan, topotecan mechanISm Inhibit topoisomerase I and prevent DNA unwinding and replication. clInIcal USe Colon cancer (irinotecan); ovarian and small cell lung cancers (topotecan). adVeRSe eFFectS Severe myelosuppression, diarrhea. mechanISm Inhibits ribonucleotide reductase \u008e\u0090 DNA Synthesis (S-phase specific). clInIcal USe Myeloproliferative disorders (eg, CML, polycythemia vera), sickle cell disease (\u2022 HbF). adVeRSe eFFectS Severe myelosuppression, megaloblastic anemia. mechanISm Monoclonal antibody against VEGF. Inhibits angiogenesis (BeVacizumab inhibits Blood Vessel formation). clInIcal USe Solid tumors (eg, colorectal cancer, renal cell carcinoma), wet age-related macular degeneration."
        },
        {
            "id": "InternalMed_Harrison_8524",
            "title": "InternalMed_Harrison",
            "content": "Class of Drugs Examples of Agents in Class Inhibitors of Mutant proteins Tyrosine kinase inhibitors Dasatinib, midostaurin, quizartinib, sorafenib IDH2 mutation inhibitor AG-221 Inhibitors of Cell Proliferation Inhibitors of Protein Synthesis and Degradation HSP-90 antagonists 17-Allylaminogeldanamycin (17-AAG), DMAG, or derivatives Nucleoside analogues Clofarabine, troxacitabine, elacytarabine, sapacitabine Compounds with Immuno-Mediated Mechanisms Antibodies CSL362 (anti-CD123), anti-CD33 (SGN33), anti-KIR Immunomodulatory Lenalidomide, interleukin 2, histamine dihydrochloride autologous HSCT (5% mortality rate), but the relapse rate is higher than with allogeneic HSCT, due to the absence of the graft-versusleukemia (GVL) effect seen with allogeneic HSCT and possible contamination of the autologous stem cells with residual tumor cells."
        },
        {
            "id": "InternalMed_Harrison_6212",
            "title": "InternalMed_Harrison",
            "content": "A number of ubiquitously expressed host molecules play critical roles in normal and pathologic angiogenesis. Proangiogenic cytokines, chemokines, and growth factors secreted by stromal cells or inflammatory cells make important contributions to neovascularization, including bFGF, transforming growth factor \u03b1 (TGF-\u03b1), TNF-\u03b1, and IL-8. In contrast to normal endothelium, angiogenic endothelium overexpresses specific members of the integrin family of ECM-binding proteins that mediate EC adhesion, migration, and survival. Specifically, expression of integrins \u03b1 \u03b2 , \u03b1 \u03b2 , and \u03b1 \u03b2 mediates spreading and migration of ECs and is required for angiogenesis induced by VEGF and bFGF, which in turn can upregulate EC integrin expression. The \u03b1v\u03b23 integrin physically associates with VEGFR2 in the plasma membrane and promotes signal transduction from each receptor to promote EC proliferation (via focal adhesion kinase, src, PI3K, and other pathways) and survival (by inhibition of p53 and increasing"
        },
        {
            "id": "Pathology_Robbins_538",
            "title": "Pathology_Robbins",
            "content": "Separation of pericytes from the abluminal surface and breakdown of the basement membrane to allow formation of a vessel sprout Migration of endothelial cells toward the area of tissue injury Proliferation of endothelial cells just behind the leading front (\u201ctip\u201d) of migrating cells Recruitment of periendothelial cells (pericytes for small capillaries and smooth muscle cells for larger vessels) to form the mature vessel Suppression of endothelial proliferation and migration and deposition of the basement membrane It has been suggested that endothelial progenitor cells are present in the bone marrow and can be recruited to promote new vessel formation. However, these cells likely play a minor, if any, role in the angiogenesis associated with the healing of most wounds. Leading (\u201dtip\u201d) cell (VEGF, Notch Formation of new vessel ECM Pericyte recruitment Elongation of vascular stalk"
        },
        {
            "id": "InternalMed_Harrison_6219",
            "title": "InternalMed_Harrison",
            "content": "release of stored VEGF and microvessel clot formation, creating more abnormal blood flow and regions of hypoxemia. C. In experimental systems, treatment with bevacizumab or blocking antibodies to VEGFR2 leads to changes in the tumor vasculature that has been termed vessel normalization. During the first week of treatment, abnormal vessels are eliminated or pruned (dotted lines), leaving a more normal branching pattern. ECs partially regain features such as cell-cell junctions, adherence to a more normal BM, and pericyte coverage. These changes lead to a decrease in vascular permeability, reduced interstitial pressure, and a transient increase in blood flow within the tumor. Note that in murine models, this normalization period lasts only for ~5\u20136 days. D. After continued anti-VEGF/VEGFR therapy (which is often combined with chemoor radiotherapy), ECs die, leading to tumor cell death (either due to direct effects of the chemotherapy or lack of blood flow)."
        }
    ],
    "scores": [
        0.037293237320479136,
        0.03659502806791891,
        0.035355279045534094,
        0.03324488841586911,
        0.03259133365698386,
        0.03190254582568236,
        0.031130484783164256,
        0.02971495162262507,
        0.028691346016408836,
        0.02714751260060053,
        0.025299735826051613,
        0.025270246260323603,
        0.025021785068514043,
        0.024066589237320947,
        0.022454890788224123,
        0.02218361009728052,
        0.022086274361483683,
        0.021946254722561186,
        0.02193783434790629,
        0.021844049497929962,
        0.021789982239264163,
        0.02175714191025386,
        0.02071945846706693,
        0.020631074107273988,
        0.020405342895150422,
        0.01930429706129027,
        0.01889483065953654,
        0.018362533692722373,
        0.017973200673995025,
        0.017555859553123575,
        0.017242040749491216,
        0.017182890855457225
    ]
}